BioHarvest Sciences Secures 4.33 Million NIS Grant from Israel Innovation Authority to Enhance AI-Powered Plant Cell Synthesis

Israel Innovation Authority Awards Second 2026 Grant to BioHarvest Sciences

On July 15, 2026, BioHarvest Sciences Inc. announced that the Israel Innovation Authority approved a 4.33 million NIS grant, approximately USD $1.4 million. The IIA, a government entity promoting Israel's innovation ecosystem, supports technology development from early research to industrial application. The announcement came from BioHarvest's dual headquarters in Vancouver, British Columbia, and Rehovot, Israel.

This is BioHarvest's second IIA grant in 2026. The initial grant supported scaling its manufacturing facility by integrating industrial automation and machine learning on the factory floor. The current grant focuses on transforming early-stage research and development through predictive artificial intelligence, addressing different phases of the company’s operations and linking laboratory discovery with commercial production.

Non-Dilutive Funding and Repayment Details

The IIA grant is structured as a non-dilutive, zero-interest loan, with no equity or equity-linked instruments issued, thereby preventing dilution of existing shareholders. Repayment will occur only upon meeting specific commercial milestones and is expected to be sourced solely from future revenues generated by the funded project. The company cautions that as a research initiative, there is no guarantee of future revenue generation, and commercialization depends on factors such as consumer preferences and market acceptance.

Integrating AI and Machine Learning into Plant Cell Culture Processes

BioHarvest's research initiative aims to shift plant cell culture from traditional trial-and-error methods to a data-driven, predictive optimization framework. The program combines bioinformatics, chemo-informatics, and AI to forecast plant cell propagation success and maximize active metabolite production.

The platform will incorporate advanced data science, machine learning, computer vision, and high-throughput digital sensing into BioHarvest’s biological development workflows. These technologies are designed to accelerate plant cell culture programs by replacing manual processes with technology-driven forecasting, monitoring, and scaling of complex plant-based compound production.

Development of a Computational Discovery Engine Utilizing Predictive Modeling and Real-Time Sensing

The funded project will expedite the creation of an advanced computational discovery engine that integrates proprietary predictive machine learning models with real-time digital sensing to rapidly identify optimal pathways and maximize bioactive yields across various plant species.

This system will be supported by secure, domain-specific scientific knowledge bases, streamlining early-stage R&D by transforming the forecasting, monitoring, and scaling of complex plant compounds. The company emphasizes this as a shift from traditional lab methods to an intelligent, data-driven discovery model but notes commercialization outcomes remain uncertain.

CEO Remarks on IIA Grant and Company Position

Dr. Zaki Rakib, Chairman and CEO of BioHarvest, stated: "We are extremely thankful for the additional support from the IIA. This grant, the second we have received this year, strengthens the Company's financial position by providing non-dilutive capital support as we implement a smarter, more efficient approach to our biological development workflows."

The CEO highlighted the dual benefits of the award: financial support without dilution and operational enhancements in biological research. No further management commentary or financial guidance was provided in the announcement.

BioHarvest’s Botanical Synthesis Technology and Business Model

BioHarvest Sciences is a leader in Botanical Synthesis, employing patented technology to cultivate plant-based compounds without growing the actual plants. The company trades on NASDAQ as BHST and on the Frankfurt Stock Exchange as 8MV0, with research operations in Rehovot, Israel, and corporate headquarters in Vancouver, British Columbia.

The company operates two main business verticals: a contract development and manufacturing organization (CDMO) serving clients seeking novel plant-based compounds, and a developer of proprietary nutraceutical health and wellness products leveraging its Botanical Synthesis platform. The technology is patented, with ongoing development of science-based, clinically focused therapeutic solutions.

Distinct Focus of the Two 2026 IIA Grants

The second IIA grant differs from the first awarded earlier in 2026. The initial grant supported scaling manufacturing through industrial automation and machine learning integration on the factory floor. The second grant targets upstream R&D, specifically early-stage discovery pipelines.

BioHarvest describes these initiatives as complementary, driving a technological transformation that bridges intelligent, data-driven laboratory discovery with autonomous commercial production. While the combined grants cover manufacturing and research, the company did not disclose aggregate financial impacts or timelines.

Forward-Looking Statements and Commercialization Risks

The announcement includes detailed forward-looking statements cautioning that actual results may differ materially from expectations. For the CDMO business, there is no assurance of additional contracts or that increased revenue will lead to higher net income due to potential rising costs.

There is no guarantee that research agreements will progress beyond contracted stages or that any developed compounds will be commercialized or generate royalties. Specifically, for the IIA-funded project, no assurance exists that future revenues will materialize. Commercial success depends on consumer preferences, advertising budgets, and other market factors deemed uncertain.

Market Trends in AI Application for Plant-Based Compound Development

The use of AI and machine learning in biotechnology and plant sciences is rapidly evolving. BioHarvest’s announcement highlights its application of these technologies to optimize plant cell culture, traditionally reliant on empirical methods. The IIA grant provides government-backed validation for this innovative research approach.

The patented Botanical Synthesis platform enables production of plant-based compounds without cultivating the plants themselves, a key differentiator. AI-driven predictive modeling aims to improve yield predictability and efficiency during R&D, though specific targets or timelines were not disclosed.

Share Price and Market Reaction Following IIA Grant Announcement

Public information at the time did not clarify immediate share price impacts. The announcement was released on July 15, 2026, via Newsfile Corp., covering BioHarvest’s NASDAQ ticker BHST and Frankfurt listing 8MV0. No trading data or market response commentary accompanied the release.

BioHarvest did not update financial guidance, revenue forecasts, or operational goals related to this grant. Readers seeking current share price information should consult live financial data sources, as this article reflects only details from the July 15, 2026 announcement.